After sorafenib remaining the one and only FDA-approved therapy for the disease for many years, the past 2 years has seen the landscape of available treatments change dramatically. 
sorafenib
Multiple multi-targeted tyrosine kinases (TKIs) have demonstrated success and garnered FDA approval both in the first- (lenvatinib) and second-line (regorafenib) settings. 
lenvatinib
Multiple multi-targeted tyrosine kinases (TKIs) have demonstrated success and garnered FDA approval both in the first- (lenvatinib) and second-line (regorafenib) settings. 
regorafenib
Additionally, promising outcomes have been seen with a number of immunotherapies, and one such agent has been approved (nivolumab). 
nivolumab